H epatitis delta virus (HDV) is a defective RNA virus that requires coinfection with hepatitis B virus (HBV) to replicate. The HDV genome is encapsidated by hepatitis B surface antigen (HBsAg), which forms the viral envelope. The virus was first identified in 1977 in the serum of long-term carriers of HBsAg and was noted to have an increased prevalence among patients with liver damage. 1 In long-term carriers of HBV, HDV infection can result in fulminant acute hepatitis or severe chronic hepatitis, often progressing to cirrhosis and hepatocellular carcinoma. [2] [3] [4] [5] [6] Eight HDV geno types have been suggested, 7, 8 and both HDV and HBV genotypes affect the clinical outcome. 9, 10 Infection with HDV genotype 1, the most prevalent genotype in Europe, the Middle East, North America, and North Africa, is associated with more severe disease than infection with genotype 2. 9, 11 Although the prevalence of HDV infection in southern Europe has declined since the introduction of vaccination against HBV, 3, 12 HDV infection -and HDV-related disease -continues to be a major health problem in several regions of the world. 13 Immigration to central Europe from areas where HDV is highly endemic has put a substantial burden on that part of the continent, where 8 to 14% of patients infected with HBV are reported to be positive for anti-HDV antibodies. [13] [14] [15] There is currently no approved therapy for infection with HDV. Oral antiviral agents, including ribavirin, lamivudine, and famciclovir, are ineffective against it. [16] [17] [18] [19] Clinical data for the more potent oral antiviral agents widely used for the treatment of chronic HBV infection, such as adefovir dipivoxil, entecavir, telbivudine, and tenofovir, are currently lacking. The effectiveness of treatment of HDV infection with interferon alfa is limited by the need for prolonged administration and high doses that are poorly tolerated. However, high-dose interferon alfa-2a therapy has been shown to reduce levels of alanine aminotransferase and HDV RNA 20 and to be associated with improved long-term clinical outcomes and survival. 21 The addition of lamivudine or ribavirin to interferon-based therapy has not improved efficacy, as compared with the use of interferon alone. 19, [22] [23] [24] Pegylated interferon (peginterferon) has been shown to be more beneficial than conventional interferon in the treatment of both chronic hepatitis C 25 and hepatitis B. 26 Three pilot studies using peginterferon alfa-2b (1.5 μg per kilogram of body weight per week) showed a sustained response to treatment (defined as un detectable levels of HDV RNA 6 months after the end of treatment) in 17 to 43% of patients treated for periods of 48 to 72 weeks. [27] [28] [29] Adefovir dipivoxil has been reported to have an effect on levels of covalently closed circular DNA (cccDNA) within infected hepatocytes in HBV infection; cccDNA acts as a template for HBsAg production. 30 A decrease in the HBsAg level may deprive HDV of the helper function of the HBV envelope protein and may therefore provide a benefit. The aim of the current study was to investigate the safety and efficacy of peginterferon alfa-2a plus adefovir dipivoxil, as compared with either drug alone, in patients with chronic HDV infection.
Me thods

Study Protocol and Oversight
The Hep-Net-International Delta Hepatitis Intervention Trial (HIDIT) was an investigator-initiated, randomized, controlled trial that was approved by the German Network of Excellence on Viral Hepatitis (Hep-Net) and operated under its auspices. 31 F. Hoffmann-La Roche and Gilead Sciences provided financial support for the study and approved the study design proposed by the investigators. The authors vouch for the veracity and completeness of the data and data analyses. The manuscript was written by the first, second, and last authors with the assistance of a representative of Elements Communication. Writing assistance was funded by F. Hoffmann-La Roche. Patients were recruited between March 2004 and September 2006, and data collection and analysis were completed in August 2009. The study was approved by the ethics committee at each participating institution. Written informed consent was obtained from each patient.
Study Population
Patients between 18 and 70 years of age who had HDV infection were eligible for inclusion if they had compensated liver disease, had been positive for HBsAg for at least 6 months and positive for anti-HDV antibodies for at least 3 months, and were positive for HDV RNA on polymerase-chainreaction assay. A description of the eligibility criteria can be found in the Supplementary Appen- 
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dix and in the study protocol, both available with the full text of this article at NEJM.org. The study was conducted in accordance with the protocol.
Study Design
Patients were stratified according to country and presence or absence of a history of interferon treatment before undergoing randomization to one of three treatment groups, and they received the assigned medication for 48 weeks. The first group included a total of 31 patients who received peginterferon alfa-2a (180 μg once weekly) plus adefovir (10 mg daily), the second group included a total of 29 patients who received peginterferon alfa-2a (180 μg once weekly) plus placebo, and the third had a total of 30 patients who received adefovir (10 mg daily) alone. Assessments for virologic end points were made at a central laboratory at weeks 24 and 48 (end of treatment), with a final clinic visit at week 72 (24 weeks after the end of treatment). At each clinic visit, all patients underwent a complete physical examination and safety assessment, and blood was taken for biochemical and virologic analysis.
Safety and Efficacy
Safety was assessed by the study investigators on the basis of adverse events reported spontaneously by study participants. In addition, plasma samples were routinely assessed for hematologic variables (e.g., leukocyte and platelet counts and levels of creatinine, alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transferase, and bilirubin). The primary end point was the achievement of undetectable levels of HDV RNA and normal levels of alanine aminotransferase at week 48. Secondary end points were based on HDV RNA levels and alanine aminotransferase levels at week 48 and week 72; levels of HBV DNA, alanine aminotransferase, and HBsAg through week 72; and histologic analysis (evaluation of biopsy specimens for fibrosis and histologic activity). Outcome measures are described in detail in the Supplementary Appendix.
Statistical Analysis
Detailed information on the procedures used for the statistical analysis is available in the Supplementary Appendix. In brief, an intention-to-treat efficacy analysis was performed for all patients receiving at least one dose of the study medication (i.e., 90 patients). Patients with missing values were categorized as not having had a response. Comparisons of specific variables were made with the use of analysis of variance or the Kruskal-Wallis test when appropriate, with P values of less than 0.05 considered to indicate statistical significance. Continuous variables were evaluated with the use of a t-test or a nonparametric test.
R e sult s
Characteristics of the Patients
Demographic and baseline clinical characteristics of the patients in the three treatment groups are shown in Table 1 and are described in further detail in the Supplementary Appendix.
Adverse Events
Of the 90 patients included in the study, 10 withdrew (5 in the group receiving peginterferon alfa2a plus adefovir dipivoxil, 3 in the group receiving peginterferon alfa-2a plus placebo, and 2 in the group receiving adefovir alone). Six of the withdrawals were due to disease progression (including 1 death from intraperitoneal bleeding as a result of hepatocellular carcinoma, 1 case of hepatic decompensation [with the patient placed on the waiting list for liver transplantation], and 1 hospitalization because of suspected hepatocellular carcinoma); 2 patients left the country, 1 patient did not comply with the treatment regimen, and 1 patient decided to withdraw because of severe malaise from interferon alfa-related adverse events.
The remaining 80 patients (89%) completed the study. Overall, 66 patients (73%) reported a total of 318 adverse events, which were more common in patients treated with peginterferon alfa-2a than in patients receiving adefovir ( Table 2 ). The adverse events were those typically associated with interferon alfa or adefovir treatment, and no unexpected adverse events occurred. The 17 serious adverse events that occurred in the study are described in detail in the Supplementary Appendix.
Outcomes
The primary outcome of the intention-to-treat analysis (normal serum levels of alanine aminotransferase and undetectable levels of HDV RNA at week 48) occurred in two patients (7%) receiving peginterferon alfa-2a plus adefovir, two (7%) receiving peginterferon alfa-2a plus placebo, and none receiving adefovir alone (P = 0.16 for pegin- terferon alfa-2a plus adefovir vs. adefovir dipivoxil, P = 0.14 for peginterferon alfa-2a plus placebo vs. adefovir dipivoxil, and P = 0.95 for peginterferon alfa-2a plus adefovir vs. peginterferon alfa2a plus placebo).
HDV RNA
At week 48, test results for HDV RNA were negative in 7 of the 31 patients (23%) treated with peginterferon alfa-2a plus adefovir dipivoxil, 7 of the 29 patients (24%) treated with peginterferon alfa-2a plus placebo, and none of the 30 patients treated with adefovir alone (P = 0.006 for peginterferon alfa-2a plus adefovir vs. adefovir dipiv oxil, and P = 0.004 for peginterferon alfa-2a plus placebo vs. adefovir dipivoxil) (Fig. 1A) . At week 72, tests for HDV RNA were negative in 8 (26%) of the patients treated with peginterferon alfa-2a plus adefovir dipivoxil, 9 (31%) of those treated with peginterferon alfa-2a plus placebo, and none of those treated with adefovir alone (P = 0.006 for peginterferon alfa-2a plus adefovir vs. adefovir dipivoxil, and P = 0.004 for peginterferon alfa-2a plus placebo vs. adefovir dipivoxil) (Fig. 1A) . Overall, the proportion of patients treated with peginterferon alfa-2a (with or without adefovir dipivoxil) who had HDV-RNA clearance was 23% (14 of 60) at week 48 and 28% (17 of 60) at week 72. There was a reduction from baseline in median HDV RNA levels in both of the groups receiving peginterferon alfa-2a (P<0.001 for weeks 24 and 48, and P = 0.02 and 0.03, respectively, for week 72) (Fig. 1B) . A reduction in median HDV RNA levels of more than 2 log 10 copies per milliliter from baseline to week 72 was observed in 8 (26%) of the patients treated with peginterferon alfa-2a plus adefovir dipivoxil, 9 (31%) of those treated with peginterferon alfa-2a plus placebo, and none of those treated with adefovir alone (P = 0.003 for peginterferon alfa-2a plus adefovir vs. adefovir dipivoxil, and P = 0.001 for peginterferon alfa-2a plus placebo vs. adefovir dipivoxil). Only 2 patients had a virologic relapse, with the reappearance of HDV RNA, after the end of treatment (1 patient in each peginterferon alfa-2a group), whereas 9 patients (4 treated with peginterferon alfa-2a plus adefovir and 5 treated with peginterferon alfa-2a plus placebo) became negative for HDV RNA during follow-up. No follow-up data on HDV RNA were available for 4 patients who were negative for HDV RNA at the end of treatment.
Alanine Aminotransferase
At week 48, the level of alanine aminotransferase was normal in 10 of 31 patients (32%) receiving peginterferon alfa-2a plus adefovir dipivoxil, 8 of 29 (28%) receiving peginterferon alfa-2a plus placebo, and 2 of 30 (7%) receiving adefovir alone (P = 0.01 for peginterferon alfa-2a plus adefovir vs. adefovir dipivoxil, and P = 0.03 for peginterferon alfa-2a plus placebo vs. adefovir dipivoxil) ( Fig. 2A) . At week 72, a total of 11 patients (35%) receiving peginterferon alfa-2a plus adefovir and 13 patients (45%) receiving peginterferon alfa-2a plus placebo had normal alanine aminotransferase levels, as compared with 3 patients (10%) receiving adefovir alone (P = 0.02 for peginterferon alfa-2a plus adefovir vs. adefovir dipivoxil, and P = 0.003 for peginterferon alfa-2a plus placebo vs. adefovir dipivoxil) ( Fig. 2A) . After the end of treatment, mean alanine aminotransferase levels increased slightly in the two groups receiving adefovir (Fig. 2B) .
HBV DNA
Median HBV DNA levels decreased until week 48 and rebounded at week 72 in all three treatment groups (for details, see the Supplementary Appendix).
HBsAg
HBsAg levels showed a marked decline only in patients receiving combination therapy, with a median decline of 0.89 log 10 IU per milliliter from baseline to week 48 (P = 0.002) and 1.12 log 10 IU per milliliter from baseline to week 72 (P<0.001). In contrast, there was no substantial effect on median HBsAg levels in patients treated with peginterferon alfa-2a plus placebo or adefovir alone, and levels remained largely stable in these two groups throughout therapy and during follow-up. A decline of more than 1 log 10 IU per milliliter in HBsAG levels from baseline to week 48 was observed in 10 patients treated with pegin ter fer on alfa-2a plus adefovir dipivoxil, 2 patients treated with peginterferon alfa-2a plus placebo, and none treated with adefovir ( Fig. 3 ) (P<0.001 for peginterferon alfa-2a plus adefovir vs. adefovir, and P = 0.02 for peginterferon alfa-2a plus adefovir vs. peginterferon alfa-2a plus placebo). In total, 2 patients treated with peginterferon alfa-2a plus adefovir had clearance of HBsAg by week 72; both had seroconversion to antiHBsAg antibodies. Patients older than 38 years (median age) were more likely to have a decline in HBsAg of more than 1 log 10 IU per milliliter at week 72 if they had received treatment with pegin ter fer on alfa-2a (29% vs. 8%, P = 0.052), but no association was found between a decline in HBsAg and sex, status with respect to alanine aminotransferase, HBV DNA, HDV RNA, HBeAg, histologic grade, or stage.
Histologic Analysis
Specimens from biopsies performed before and after treatment were available for a total of 59 patients (65% of all treated patients). Analysis of paired specimens revealed approximately equal distributions of patients with deterioration, those with improvement, and those with no change in each treatment group (for details, see the Supplementary Appendix).
Discussion
Our study showed that a 48-week course of pegin ter fer on alfa-2a, alone or in combination with (7) 0 * The adverse events listed are those that were reported by at least three patients in at least one of the three study groups. The term "serious adverse event" is defined in the protocol, available at NEJM.org. † For these events there was a significant difference in the number per study group (P = 0.03 for pyrexia and 0.01 for dry mouth, calculated with the use of chisquare analysis). ‡ P = 0.004 for the comparison of the groups receiving peginterferon alfa2a, with or without adefovir dipivoxil, with the group receiving adefovir dipivoxil alone. adefovir dipivoxil, significantly reduced HDV RNA levels, with 28% of patients receiving the drug having clearance of HDV RNA 24 weeks after the end of treatment. In contrast, treatment with adefovir dipivoxil alone had no appreciable effect on HDV replication; none of the patients who received this treatment had clearance of HDV RNA, and none had a decline from baseline HDV RNA levels of more than 2 log 10 copies per milliliter. The predefined primary end point of the study, normal serum levels of alanine aminotransferase and undetectable HDV RNA at week 48, was achieved in few patients -7% of those treated with peginterferon alfa-2a, with or without adefovir dipivoxil, and none of those treated with adefovir dipivoxil alone. Since alanine aminotransferase levels frequently remain elevated during treatment with peginterferon alfa, 25 this finding was not completely unexpected. On the other hand, levels of alanine aminotransferase normalized in several patients in our study, who nonetheless remained positive for HDV RNA, a finding also reported in the pilot studies of peginterferon alfa-2b. 29 Clearance of HDV RNA in patients treated with interferon has been reported previously.
The New England
Considerable decreases in HDV RNA levels have been reported after 1 year of treatment with high-dose interferon alfa (9 million units three times a week), 20 results that were associated with long-term improvements in hepatic function and histologic findings. 21 A number of case reports and reports on small studies have noted reductions in or clearance of HDV RNA as a result of treatment with peginterferon. [27] [28] [29] 32 With regard to efficacy, the results of our larger study are in general accordance with these reports.
In contrast with the findings for peginterferon in the treatment of HDV and HBV infection, we observed that in several patients, HDV RNA cleared between the end of treatment and follow-up 24 weeks later. Earlier studies also showed that a decrease in HDV RNA levels may occur late in the course of therapy, and in some cases even after the end of treatment, with both conventional interferon and peginterferon. [27] [28] [29] Further studies are needed to determine whether patients with a slow response to treatment who have clinically significant declines in HDV RNA levels during treatment without becoming HDV RNA-negative would benefit from a longer period of treatment. In both groups receiving peginterferon alfa2a, HDV RNA levels were significantly lower at week 48 than at baseline (P<0.001 for both groups). At week 72, HDV RNA levels were slightly reduced as compared with baseline in both these groups (P = 0.02 for the group receiving peginterferon alfa2a plus adefovir dipivoxil, and P = 0.03 for the group receiving peginterferon alfa2a plus placebo), but levels were increased in the group receiving adefovir dipivoxil alone (P = 0.02).
The In line with earlier studies of the use of oral anti-HBV agents, monotherapy with adefovir dipivoxil had no appreciable effect on HDV RNA levels in our study, and none of the patients treated with adefovir alone had clearance of HDV RNA. Currently, we would not recommend the use of nucleoside or nucleotide monotherapy for HDV infection in patients with suppressed or very low HBV replication. 13 The clearance of HBsAg is considered to be the closest outcome to a cure in chronic HBV infection and is therefore recognized as the ideal end point of therapy. 34 Since the virus needs HBsAg to produce infectious viral particles, reducing HBsAg levels, or even achieving clearance of HBsAg, is of considerable relevance in the treatment of infection with HBV and HDV. Patients with chronic HBV infection in whom a sustained virologic response to interferon-based therapy is achieved have an increased likelihood of HBsAg clearance during long-term follow up. 35, 36 HBsAg clearance is not generally seen in HBeAg-negative patients treated with nucleoside or nucleotide analogues, including lamivudine, entecavir, and telbivudine. 32, 37, 38 In our study, the combination of peginterferon alfa-2a and adefovir resulted in a more pronounced decrease in serum HBsAg levels than did either agent alone; approximately one third of patients receiving combination therapy had a decline in the HBsAg level of at least 1 log 10 IU per milliliter. The apparently higher rate of HBsAg decline in patients receiving combination therapy may be related to differences in patient characteristics or to the mechanisms of action or the potency of adefovir as compared with lamivudine.
In the current study, the absence of any apparent differences in histologic scores in analyses of paired biopsy samples may reflect the shorter follow-up period in our study, as compared with that in previous studies, or sample bias due to the small numbers of patients with paired biopsy samples. More patients in the combination-therapy group had a worsening of fibrosis scores and a higher number of patients receiving peginterferon alfa-2a alone had a worsening of scores for histologic activity. It is noteworthy that biopsies were performed at the end of treatment, rather than 24 weeks after the end of treatment, as has been the case in most trials investigating the use of peginterferon alfa-2a for hepatitis B and C. Thus, more data on the results of biopsies performed at follow-up after the completion of treatment would be needed to answer the question of whether peginterferon alfa-2a worsens certain histologic features of infection with HDV. The withdrawal rate for the patients in our study (all of whom had HDV infection) who were treated with peginterferon alfa-2a was 11% -a rate that is not dissimilar to that in large-scale studies of peginterferon alfa-2a in the treatment of chronic HBV monoinfection. 39 The one patient in our study who had hepatic decompensation during treatment with peginterferon alfa-2a had a baseline platelet count of 74,000 per cubic millimeter after an initial screening count of 75,000 per cubic millimeter, which was in line with the study inclusion criteria. Thus, we would recommend caution in the use of peginterferon alfa-2a therapy for patients whose platelet counts are below 90,000 per cubic millimeter.
In conclusion, treatment with peginterferon alfa-2a for 48 weeks resulted in sustained HDV RNA clearance in more than 25% of patients and a sustained biochemical response in 40%.
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